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ABSTRACT Staphylococcus aureus expresses a panel of cell wall-anchored adhesins,
including proteins belonging to the microbial surface components recognizing
adhesive matrix molecule (MSCRAMM) family, exemplified by the serine-aspartate re-
peat protein D (SdrD), which serve key roles in colonization and infection. Deletion
of sdrD from S. aureus subsp. aureus strain NCTC8325-4 attenuated bacterial survival
in human whole blood ex vivo, which was associated with increased killing by hu-
man neutrophils. Remarkably, SdrD was able to inhibit innate immune-mediated
bacterial killing independently of other S. aureus proteins, since addition of recombi-
nant SdrD protein and heterologous expression of SdrD in Lactococcus lactis pro-
moted bacterial survival in human blood. SdrD contributes to bacterial virulence in
vivo, since fewer S. aureus subsp. aureus NCTC8325-4 ΔsdrD bacteria than bacteria of
the parent strain were recovered from blood and several organs using a murine in-
travenous infection model. Collectively, our findings reveal a new property of SdrD
as an important key contributor to S. aureus survival and the ability to escape the
innate immune system in blood.
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Staphylococcus aureus is a human commensal that persistently colonizes the anteriornares of healthy individuals but is also a leading cause of multiple community-
acquired and nosocomial infections ranging from mild skin and soft tissue infections
to life-threatening invasive diseases, including sepsis and endocarditis (1). The
bacterium expresses various cell wall-anchored proteins, including the microbial sur-
face components recognizing adhesive matrix molecules (MSCRAMMs). Among the
MSCRAMMs are the clumping factor (Clf)–serine-aspartate repeat (Sdr) group of pro-
teins, including SdrD (2). SdrD promotes the adherence of S. aureus to desquamated
nasal epithelial cells (3) and to human keratinocytes in vitro (4) and contributes to
abscess formation in vivo (5).
Neutrophils, the most abundant circulating phagocytes of the innate immune
system, play an important role in protection against pathogen dissemination (6, 7).
Decoration of bacteria with opsonins, i.e., specific immunoglobulins and components
of the complement system, activates the phagocytic machinery through interaction
with the corresponding neutrophil Fc receptors or complement receptors (reviewed in
reference 8). The generation of reactive oxygen species (ROS) through activation of
NADPH oxidase and expression of antibacterial molecules in granules is a key mecha-
nism for neutrophil-mediated killing of phagocytized bacteria, while elaboration of
DNA-based neutrophil extracellular traps (NETs) promotes extracellular microbial killing
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(reviewed in reference 8). A crucial role of neutrophils in controlling S. aureus infection
is evident through the study of patients with immune defects (reviewed in reference 9);
for example, cancer patients with neutropenia (10) or individuals with genetic defects
of neutrophil function (11, 12) demonstrate markedly increased rates of S. aureus
infection.
S. aureus can enter the bloodstream through several routes (1), whereupon a
sophisticated and synergistic group of neutrophil resistance mechanisms, including
antioxidant systems, factors that bind or inactivate granule components, and mecha-
nisms to avoid complement opsonization and phagocytosis, enhance the in vivo fitness
of the organism (6, 13, 14). Impairment of neutrophil intracellular killing allows S. aureus
to survive long enough within these cells in the bloodstream to travel to and infect
distant sites (reviewed in references 6 and 15).
A higher prevalence of the sdrD gene among S. aureus isolates from patients with
bone infections has been reported (16, 17). In addition, the expression of sdrD is
upregulated upon incubation in fresh human blood ex vivo (18). These data raised the
possibility that SdrD could play a role during systemic infection. To date the interaction
of SdrD with host innate immune components has not been studied. The current work
evaluates whether SdrD may aid the pathogen in immune evasion. Using an isogenic
mutant with a deletion of the sdrD gene, we found a significant contribution of SdrD
in S. aureus resistance to killing by innate immune components present in blood in vitro
and bacterial clearance from tissues and blood during systemic infections.
RESULTS
Expression profile of sdrD. The expression profile of sdrD was assessed using S.
aureus subsp. aureus NCTC8325-4 expressing an sdrD promoter-green fluorescent
protein (GFP) fusion construct. In regular bacterial growth medium (tryptic soy broth
[TSB]), the level of sdrD promoter-driven GFP expression was low and slightly decreased
during early exponential growth. Thereafter, the sdrD promoter activity increased when
bacteria entered late exponential phase and continued to increase during the station-
ary phase (Fig. 1A).
We also tested SdrD protein expression by immunoblotting using SdrD-specific
antibodies. SdrD was detected within the bacterial lysate of NCTC8325-4 and was
detected most abundantly at early stationary phase but was not detected in the
isogenic mutant, NCTC8325-4 ΔsdrD (Fig. 1B). Similar to a previous report for SdrC (19),
SdrD was detected in cell-free concentrated culture supernatants, particularly in late
exponential phase (Fig. 1B), which may have been due to proteolytic release and/or cell
death.
A previous study showed that sdrD expression was upregulated in the presence of
human whole blood (18). As neutrophils are the most abundant leukocytes in blood, we
examined sdrD promoter activity in the presence of freshly isolated human neutrophils.
sdrD promoter-driven expression of GFP in NCTC8325-4 occurred after 1.5 and 3.5 h
upon coincubation with neutrophils in vitro at multiplicities of infection (MOI) of 20 (Fig.
1C) and 10 (results not shown). sdrD promoter activity was independent of S. aureus
extracellular or intracellular localization (Fig. 1C, 3.5 h).
SdrD promotes S. aureus survival in blood. Since sdrD promoter activity increased
in the presence of neutrophils (Fig. 1C) and in the presence of blood (18), we
hypothesized that SdrD may affect bacterial survival in blood. To address this
hypothesis, NCTC8325-4 and NCTC8325-4 ΔsdrD were incubated in 80% freshly
drawn blood, using hirudin as an anticoagulant. After 3 h of incubation in human
blood, 25% of the SdrD-expressing inoculum survived, while only 7% of the isogenic
mutant was recovered (P  0.05) (Fig. 2A). The approximately 3.5-fold higher rate
of survival of the parent strain was not attributable to differences in bacterial
growth rates between NCTC8325-4 and its isogenic mutant (see Fig. S1A in the
supplemental material) (4). The SdrD-mediated increase in bacterial survival was
also observed in mouse blood (Fig. 2B).
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To corroborate the specificity of SdrD-mediated bacterial survival in blood, a blood
survival assay was performed using the complementation and heterologous expression
systems in NCTC8325-4 ΔsdrD and Lactococcus lactis. As seen in Fig. 2C, NCTC8325-4
ΔsdrD and L. lactis ectopically expressing SdrD survived better in human blood than L.
lactis carrying only the empty vector (Fig. 2C, left and right, respectively). Moreover,
addition of purified, recombinant full-length SdrD (rSdrD) increased the rates of survival
of NCTC8325-4 and its isogenic mutant in human whole blood 1.3- and 2.4-fold,
respectively (Fig. 2D). Finally, a blood survival assay was performed using Staphylococ-
cus haemolyticus and Escherichia coli in the absence or presence of exogenously
administered rSdrD. The presence of recombinant SdrD strongly promoted the survival
of both strains in human whole blood (Fig. 2E), underscoring the ability of SdrD to
protect the pathogen from immune killing.
In summary, these lines of evidence demonstrate that the presence of SdrD im-
proves the survival of bacteria in human and mouse blood.
The presence of SdrD does not affect S. aureus phagocytosis ex vivo. To assess
whether the SdrD-mediated increase in survival in blood was due to variation in
bacterial uptake by neutrophils, we tested its contribution in a human whole-blood
phagocytosis assay. Fluorescence-labeled NCTC8325-4 and NCTC8325-4 ΔsdrD were
incubated with 80% human whole blood. Neutrophil-mediated phagocytosis was
analyzed by flow cytometry. We observed that the levels of uptake of NCTC8325-4 and
NCTC8325-4 ΔsdrD by human neutrophils were comparable (Fig. 2F). Similar results
FIG 1 sdrD promoter activity and SdrD protein expression under different growth conditions. (A) Promoter activity of sdrD during growth
in TSB using NCTC8325-4 harboring the sdrD-GFP reporter construct (S. aureus subsp. aureus psdrD-GFP). Data represent the means 
SEMs from an individual experiment. The experiments were performed twice in triplicate. RFU, relative fluorescence units. (B) Immuno-
blotting of the bacterial lysates and the culture cell-free supernatant of NCTC8325-4 and its isogenic mutant, NCTC8325-4 ΔsdrD, using
anti-SdrD antibody on the bacterial lysates and the culture cell-free supernatant. A representative Western blot is shown. (C) Promoter
activity of sdrD evaluated by fluorescence microscopy using NCTC8325-4 harboring psdrD-GFP in the presence of freshly isolated human
neutrophils. (Top) Live imaging was performed after 0.2, 1.5, and 3.5 h using fluorescence microscopy; (bottom) bright-field and GFP
merged images. The white boxes in the first column labeled 3.5 h are enlarged in the second column labeled 3.5 h. The experiment was
performed at an MOI of 20. Arrows, S. aureus subsp. aureus psdrD-GFP. The sizes of the scale bars are indicated.
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were obtained when 25 and 50% human whole blood was used and rSdrD was adding
to the assay mixture (Fig. S2A and B). Thus, the SdrD-mediated increased survival in
human whole blood is not explained by differences in phagocytosis.
SdrD attenuates neutrophil-mediated S. aureus killing. To further probe how
SdrD may contribute to bacterial survival in human blood, the role of SdrD in S. aureus
survival in the presence of neutrophils was investigated. For this purpose, plasma-
opsonized S. aureus subsp. aureus (NCTC8325-4 and its isogenic mutant) and L. lactis
(with or without an expression plasmid carrying SdrD) were coincubated with neutro-
phils for 1 h in the presence of human plasma and plated for determination of the
number of surviving bacteria. Expression of SdrD significantly increased the rate of
survival of the parent strain (Fig. 3A) compared to that of the isogenic mutant. The
increased survival was not due to differences in bacterial growth in RPMI 1640 sup-
plemented with human serum albumin (HSA), Todd-Hewitt broth (THB), or plasma-HSA
(Fig. S1A and B). Expression of SdrD also mediated enhanced survival of L. lactis in the
presence of neutrophils (Fig. 3B). We then tested whether exogenously added SdrD
promoted the survival of S. aureus in the presence of neutrophils and found that
addition of rSdrD increased the rates of survival of both NCTC8325-4 and NCTC8325-4
ΔsdrD (Fig. 3C). These results reveal that SdrD can contribute to neutrophil resistance.
S. aureus expressing SdrD does not show increased survival in NETs but
influences neutrophil viability. The role of NETs in the extracellular killing of patho-
gens has been previously demonstrated (reviewed in reference 20). To determine
FIG 2 SdrD promotes S. aureus survival in human and mouse whole blood. (A and B) SdrD increases the rate of survival of NCTC8325-4 in human
blood (A) and in mouse blood (B). The rate of survival for bacteria inoculated at time zero was arbitrarily set equal to 100%, and the rate of survival
after 3 h is presented as a percentage of the number of bacteria in the inoculum. (C) Transcomplementation of NCTC8325-4 ΔsdrD with
plasmid-expressed SdrD (left) and ectopic expression of SdrD in L. lactis (right) restore survival in human whole blood. Bacterial survival was
analyzed by viability counting. The rate of survival is presented as described in the legend to panel A. (D) Influence of rSdrD (12 g/ml) on the
survival of NCTC8325-4 and NCTC8325-4 ΔsdrD in human whole blood. The rate of survival in untreated blood was arbitrarily set equal to 1, and
the rate of bacterial survival in blood treated with rSdrD is represented as the fold change. (E) The survival of E. coli and S. haemolyticus in human
whole blood is increased in the presence of rSdrD (12 g/ml). The fold change in bacterial survival is presented as described in the legend to
panel D. (F) NCTC8325-4 and its mutant, NCTC8325-4 ΔsdrD, were labeled with FITC, and 40 l of different concentrations of inoculum (1 
108 or 1  107 CFU/ml) was incubated with human whole blood. Data represent the geometric mean of the fluorescence intensity (GMFI). Data
are presented as the means  SEMs from at least three independent experiments. Statistical analysis was performed by Student’s t test. Significant
differences are indicated by asterisks. *, P  0.05; ***, P  0.001; ****, P  0.0001.
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whether SdrD protected S. aureus against NET-mediated extracellular killing, neutro-
phils were treated with phorbol 12-myristate 13-acetate (PMA) for 4 h to induce
maximal NET production before addition of bacteria. The rates of survival of
NCTC8325-4 and NCTC8325-4 ΔsdrD were comparable after 30 min of exposure to NETs
(Fig. 3D). The same results were obtained using opsonized bacteria (results not shown).
These results suggest that SdrD does not contribute to S. aureus survival in NETs.
Next, we asked whether resistance to neutrophil killing influenced neutrophil via-
bility. Freshly isolated human neutrophils were infected with NCTC8325-4 and
NCTC8325-4 ΔsdrD at MOIs of 10 and 20. Cell viability was monitored by measuring the
amount of intracellular lactate dehydrogenase (LDH) released after 1 and 3 h. The
percentage of LDH released was less than 10% and independent of SdrD expression
after 1 h of infection at MOIs of 10 and 20 (results not shown). After 3 h of coincubation,
NCTC8325-4 induced a significantly higher level of LDH release from neutrophils than
NCTC8325-4 ΔsdrD (Fig. 3E), indicating that the higher rate of survival of SdrD-
containing bacteria in the presence of neutrophils may promote or, indeed, in part,
reflect pathogen-induced cell death.
SdrD promotes S. aureus survival in blood and multiple organs in a murine
intravenous infection model. Finally, we evaluated whether SdrD impacted S. aureus
virulence in vivo. CD-1 mice were injected intravenously with NCTC8325-4 or
NCTC8325-4 ΔsdrD. After 4 h and 4 days, organs and blood were harvested and the
FIG 3 SdrD promotes S. aureus survival in the presence of human neutrophils. (A and B) Survival of NCTC8325-4 and NCTC8325-4 ΔsdrD
(A) and L. lactis containing sdrD-pMG36e or the empty vector (B) after incubation with freshly isolated human neutrophils. The bacteria
were opsonized with plasma and exposed to purified neutrophils before bacterial survival was analyzed by viability counting. The rate of
survival for the bacterial inoculum was arbitrarily set equal to 100%, and the rate of survival of the bacteria after 1 h is presented as a
percentage of the number of bacteria in the inoculum. (C) Influence of rSdrD on survival of plasma-opsonized NCTC8325-4 or
NCTC48325-4 ΔsdrD in the presence of human neutrophils. Bacterial survival was analyzed by viability counting. The survival of untreated
neutrophils was arbitrarily set equal to 1, and the rate of bacterial survival in the neutrophils treated with rSdrD is presented as the fold
change. (D) PMA-induced neutrophils were used to perform a NET-mediated killing assay using NCTC8325-4 or NCTC48325-4 ΔsdrD at an
MOI of 1. The bacteria that were incubated without neutrophils served as controls, and the rate of survival for these bacteria was arbitrarily
set equal to 100%. The rate of survival of these bacteria after 30 min is presented as a percentage of the number of bacteria in the
inoculum. (E) Freshly isolated neutrophils were exposed to NCTC8325-4 or NCTC48325-4 ΔsdrD at an MOI of either 10 or 20. Percent
viability was calculated by measuring the amount of LDH released from the cytosol of damaged cells into the supernatant. Data represents
means  SEMs from at least three independent experiments. Statistical analysis was performed by Student’s t test. Significant differences
are indicated by asterisks. *, P  0.05; **, P  0.01; ***, P  0.001.
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numbers of CFU were determined. Deletion of sdrD resulted in significantly decreased
S. aureus loads in the blood at 4 h postinfection (Fig. 4A, left), while the levels of
recovery of NCTC8325-4 and NCTC8325-4 ΔsdrD from kidney, spleen, and liver were
comparable. At 4 days postinfection, a significantly higher level of recovery of
NCTC8325-4 than NCTC8325-4 ΔsdrD was apparent in blood as well as in spleen, kidney,
and liver (Fig. 4A, right).
Histopathological evaluation of kidney as a target organ for S. aureus in a bacteremia
model of infection (21) was performed to determine the extent of NCTC8325-4-induced
organ damage. Tissues from uninfected mice and NCTC8325-4 ΔsdrD-infected mice
were included for comparison (Fig. 4B). Examination of the kidneys at 4 days after
intravenous inoculation of S. aureus revealed increased neutrophil infiltration in 2/6
examined mice inoculated with NCTC8325-4 (Fig. 4B, right), while increased neutrophil
infiltration was not observed in the kidneys of mice infected with NCTC8325-4 ΔsdrD
(Fig. 4B, middle).
Collectively, these data suggest the contribution of SdrD to S. aureus virulence in
vivo.
DISCUSSION
Several of the MSCRAMM proteins are multifunctional and play a role in adhesion,
invasion, and/or immune evasion (2). MSCRAMMs play a significant role in life-
FIG 4 SdrD increases the bacterial burden in a murine systemic infection model. (A) The bacterial loads in the kidney, liver, spleen, and
blood (number of CFU per gram for organs and number of CFU per milliliter for blood) of 8-week-old female CD-1 mice were enumerated
4 h and 4 days after systemic infection with NCTC8325-4 and NCTC8325-4 ΔsdrD. The data represent the means  SEMs from an
individual experiment for data obtained at 4 h postinfection and two independent experiments for data obtained at 4 days
postinfection. Statistical analysis was performed by Student’s t test. Significant differences are indicated by asterisks. *, P  0.05; **,
P  0.01. (B) Thin sections of H&E-stained uninfected kidney tissue and kidney tissue infected with S. aureus subsp. aureus
NCTC8325-4 and NCTC8325-4 ΔsdrD collected on day 4 postinfection were analyzed by light microscopy. Arrows, infiltrate of
neutrophils. The sizes of the scale bars are indicated.
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threatening infections, such as sepsis, pneumonia, and endocarditis, as well as pros-
thetic device infections (2). Indeed, studies in mice have revealed that sortase A S.
aureus mutants are less virulent than wild-type S. aureus strains in bloodstream
infections (22) and less able to form abscesses in mice (22, 23). In addition, ClfA, ClfB,
IsdA, IsdB, and SdrD were also found to contribute to the general process of infection
in vivo (5).
Approximately 15% of S. aureus genes encode proven or putative virulence factors
(24). We hypothesized that SdrD may be a virulence factor since sdrD is upregulated in
the presence of human whole blood (19). Neutrophils are the most abundant immune
cell type in blood, and here we found induction of sdrD-driven GFP expression over
time in the presence of neutrophils independently of phagocytic uptake of bacteria
(Fig. 1C). Upon exposure to human plasma, bacterial engulfment by neutrophils is
strongly promoted by opsonization of the microbe with either complement activation
products at the C3 level (C3b, iC3b) or antibodies (25–27). The interference of certain
MSCRAMMs, such as ClfA, SdrE, and collagen adhesin (Cna), with complement-
mediated opsonization and bacterial killing by neutrophils has been previously dem-
onstrated (28–32). An ex vivo human whole-blood assay was performed using
NCTC8325-4 and sdrD mutant (NCTC8325-4 ΔsdrD) strains in the presence of staphy-
lococcal complement inhibitor (SCIN), which blocks the activity of the C3 convertases
on the bacterial surface (27). In contrast to ClfA and SdrE, SdrD increases bacterial
survival in whole blood independently of impaired C3b deposition (results not shown)
and phagocytosis (Fig. 2F and S2).
SdrD provides a survival advantage to opsonized bacteria in the presence of
neutrophils (Fig. 3A to C). The intracellular survival of S. aureus within neutrophils has
been previously demonstrated (33–35), and spontaneous microbial escape through
host cell lysis may ensue (33, 34), contributing to systemic infection in vivo (35).
Resistance to killing and survival inside neutrophils are ways for S. aureus to subvert
innate immune responses (34; reviewed in reference 7). Moreover, resistance to killing
can contribute to bacterial spread by allowing the phagocytic cell to serve as a
transport vehicle (reviewed in references 6, 8, and 15). The SdrD-mediated increase in
the rate of bacterial survival in blood, resistance to neutrophil killing, and spread in the
host may indeed be consequences of host cell lysis, since SdrD-expressing NCTC8325-4
caused increased neutrophil lysis after 3 h of incubation in vitro (Fig. 3E). One mech-
anism of SdrD contributing to S. aureus virulence thus appears to be the counteracting
of neutrophil defenses, which thereby enhances bacterial spread in the host. In
agreement with this, a significantly higher bacterial load of S. aureus subsp. aureus
NCTC8325-4 was found in multiple organs of infected mice at 4 days postinfection than
in isogenic mutant-infected mice (Fig. 4A, right). However, the exact mechanism by
which SdrD increases bacterial survival and influences the viability of neutrophils
remains elusive.
SdrD-expressing S. aureus bacteria showed increased survival in vivo (Fig. 4A), which
suggests a role of SdrD in S. aureus resistance to immune clearance and systemic
disease pathogenesis. Infection with S. aureus subsp. aureus NCTC8325-4 resulted in
local neutrophil accumulation in the kidney tissues (Fig. 4B). Several MSCRAMMs,
including SdrD, have previously been found to be required for S. aureus abscess
formation, where bacteria are protected against host immunity through pseudocapsule
formation in a neutrophil-rich site (5). The molecular mechanism for this remains
elusive, but SdrD is assumed to be involved at stage II, where neutrophils, eventually
with surviving intracellular S. aureus, attract a massive infiltrate of immune cells,
including additional neutrophils (5). Moreover, exposure of the parent strain to pooled
human plasma prior to the neutrophil killing assay increased NCTC8325-4 resistance to
clearance by immune cells. S. aureus expresses multiple virulence factors, e.g., clumping
factor A (ClfA) and clumping factor B (ClfB) (36) and bone sialoprotein-binding protein
(BbP) (37), that utilize plasma coagulation proteins to protect the bacteria from immune
defense and promote bacterial proliferation and persistence. However, whether SdrD
specifically attracts clotting factors from the plasma to the bacterial surface and
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whether this is a prerequisite for abscess formation as a requirement for S. aureus
persistence in host tissues remain to be determined.
There is considerable functional redundancy among staphylococcal virulence factors
in subverting their host defense targets. Thus, identification of individual virulence
factors in a well-armed clinical isolate poses various challenges. We took advantage of
the laboratory strain NCTC8325-4, which does not express SdrE (38), is capsule negative
(see references 39 and 40 and references therein), and has a defect in the expression
of ClfA (41, 42). The use of such a strain facilitates the identification of a whole-blood
survival phenotype conferred by SdrD, since functional redundancy is less prominent.
Our results were confirmed by use of a surrogate strain expressing SdrD (Fig. 2C, right)
and clearly add credence to the mechanistic role of SdrD in immune evasion. Whether
the immune-evasive function of SdrD contributes to pathogenesis in clinical isolates
has yet to be established. However, the presence of MSCRAMMs varies among strains
(38), and as all S. aureus clones have the potential to cause invasive infections under the
right circumstances (37, 38), SdrD may be of special importance for strains lacking
certain other immune-evasive surface proteins.
In summary, using in vitro and in vivo models of systemic infection, we found that
SdrD increased the rate of S. aureus survival, which may result in increased bacterial
fitness in the host. A definitive ligand for SdrD in human whole blood remains elusive,
and further research is merited to probe the precise molecular mechanisms underlying
SdrD-mediated immune evasion by a well-armed clinical S. aureus isolate.
MATERIALS AND METHODS
Bacterial strains and growth conditions. S. aureus subsp. aureus NCTC8325-4, S. aureus subsp.
aureus NCTC8325-4 ΔsdrD, Lactococcus lactis MG1363 expressing SdrD (sdrD-pMG36e), and L. lactis
MG1363 expressing the empty vector (pMG36e) have been described previously (4). Moreover, the
sdrD-pMG36e and pMG36e constructs (4) were used to complement NCTC8325-4 ΔsdrD through
electroporation (100- resistance, 25-F capacitance, and 2.5-kV voltage). E. coli ATCC 25922 (43) and
Staphylococcus haemolyticus 51-30 (a clinical isolate recovered from blood; Rikshospitalet, Oslo, Norway)
were also included.
Overnight cultures of S. aureus or L. lactis were diluted 1:100 in tryptic soy broth (TSB; Sigma-Aldrich,
Germany) or SMG17 (M17 broth supplemented with 0.5 M sucrose [Sigma-Aldrich, Germany] and 0.5%
glucose [Sigma-Aldrich, Germany]) and incubated at 37°C and 220 rpm or 30°C without shaking,
respectively. S. haemolyticus and E. coli were grown in TSB or brain heart infusion (BHI), respectively.
Bacterial growth was monitored by determination of the optical density at 600 nm (OD600). Bacteria were
harvested at an OD600 of 0.8, pelleted by centrifugation, washed twice in phosphate-buffered saline (PBS;
Biochrom, Germany), and diluted to the selected number of CFU per milliliter or OD600 in RPMI 1640
(Gibco, Life Technologies, UK) containing 0.05% human serum albumin (HSA; Sanquin, Amsterdam, The
Netherlands) or 2% (vol/vol) fetal bovine serum (FBS; Invitrogen Life Technologies, USA), depending on
the experimental setting.
sdrD gene expression using S. aureus subsp. aureus psdrD-GFP. Expression of sdrD in S. aureus
subsp. aureus NCTC8325-4 was evaluated using a reporter construct. The S. aureus subsp. aureus
sdrD-GFP reporter strain was described previously (4) and was subsequently used to assess sdrD
expression during growth in TSB medium. An overnight culture of S. aureus subsp. aureus NCTC8325-4
harboring the sdrD reporter construct (S. aureus subsp. aureus psdrD-GFP) was diluted 1:100 in pre-
warmed TSB medium, incubated at 37°C under shaking conditions, and harvested at an OD600 of 0.4. The
bacteria were pelleted, washed in PBS, and diluted in TSB medium. Fluorescence was measured under
shaking conditions using a Synergy H1 hybrid reader (BioTek, USA) with excitation and emission of 488
and 520 nm, respectively. A control sample of S. aureus subsp. aureus NCTC8325-4 without the GFP
reporter construct was included for background correction.
SdrD protein expression profile. Expression of the SdrD protein was assessed by immunoblot
analysis. Lysates of S. aureus subsp. aureus NCTC8325-4 and the isogenic NCTC8325-4 ΔsdrD mutant were
prepared for Western blotting as described previously (4). To assess the release of SdrD, the culture
supernatant was filter sterilized (pore size, 0.22 m) to remove intact bacterial cells and concentrated
using an Amicon Ultra 50K centrifugal filter device (Millipore Corp., USA). Expression of SdrD in the
bacterial pellet and supernatant was evaluated by immunoblotting using SdrD A region-specific (a kind
gift from Elisabet Josefsson) (primary) and polyclonal swine anti-rabbit immunoglobulin (Dako, Denmark)
(secondary) antibodies.
Fluorescence microscopy analysis of sdrD expression upon coculture with neutrophils. Expres-
sion of sdrD in S. aureus subsp. aureus NCTC8325-4 in the presence of freshly isolated neutrophils was
evaluated using an sdrD promoter-GFP reporter construct as described previously (44). Neutrophils were
freshly isolated from heparinized venous blood of healthy volunteers using Histopaque (Sigma-Aldrich,
Germany)-Ficoll (GE Healthcare, Sweden) or 1-step Polymorphprep solution (Fresenius Kabi Norge AS,
Norway) gradient centrifugation. S. aureus subsp. aureus psdrD-GFP was prepared as described above in
“sdrD gene expression using S. aureus subsp. aureus psdrD-GFP” with minor modifications (44). Neutro-
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phils (2  105) in RPMI 1640 (no phenol red)–FBS were added to a 96-well plate (Corning, USA). Bacteria
were added to the neutrophils at a multiplicity of infection (MOI) of 10 or 20. The plate was incubated at 37°C
in a CO2 incubator (5% CO2). Representative live images were collected by a Zeiss AxioObserver D1
microscope (Zeiss, Germany) using both bright-field and GFP fluorescence at times of 0.2, 1.5, and 4 h.
Blood survival assay. Blood samples from healthy volunteers or CD-1 mice were collected in tubes
containing hirudin (Roche, Switzerland) as the anticoagulant to preserve complement activity. One
hundred sixty microliters of freshly drawn blood was mixed with 20 l volumes containing S. aureus
(1  107 CFU/ml), S. haemolyticus (1  106 CFU/ml), or E. coli (1  107 CFU/ml) or 40 l of L. lactis
(1  108 CFU/ml) in RPMI 1640 –HSA. When applicable, 20 l of RPMI 1640 –HSA or recombinant
full-length SdrD (rSdrD) (4) in RPMI 1640 –HSA was added to the samples in siliconized tubes (Sigma-
Aldrich, Germany) at a final concentration of 12 g/ml. After incubation for 3 h at 37°C on a horizontal
rotator, the blood cells were lysed by addition of 1 ml ice-cold H2O supplemented with 0.3% saponin
(Sigma-Aldrich, Germany). Bacterial survival was evaluated by serial dilution on blood or Todd-Hewitt
broth (THB) agar plates. Percent survival was determined by comparing the number of surviving bacteria
to the number of bacteria in the inoculum.
Growth curves for S. aureus subsp. aureus NCTC8325-4 and NCTC8325-4 sdrD. S. aureus subsp.
aureus NCTC8325-4 and NCTC8325-4 ΔsdrD were grown overnight in THB. On the next day, the bacteria
were washed twice in PBS, resuspended in RPMI 1640 –HSA or RPMI 1640 supplemented with 5%
bacteriologic medium (THB), and added to 96-well plates (Corning, USA) in a total volume of 200 l.
Growth was monitored by measuring the OD600 every 15 min for 24 h under shaking conditions using
a Bioscreen CMBR machine (Growth Curves USA). Bacterial growth in RPMI 1640 –HSA in the presence of
plasma was also quantified using serial dilutions on THB agar plates.
Whole-blood phagocytosis. For fluorescent labeling, bacteria were resuspended in PBS containing
0.5 mg/ml fluorescein isothiocyanate (FITC; Sigma-Aldrich, Germany) for 20 to 30 min on ice and
protected from light. Bacteria were washed extensively in PBS and then resuspended in RPMI 1640 –HSA
to an OD600 of 0.4. Forty microliters of FITC-labeled S. aureus subsp. aureus NCTC8325-4 and NCTC8325-4
ΔsdrD (1  108 or 1  107 CFU/ml) was incubated for 15 to 30 min at 37°C with freshly isolated human
blood (80%, 50%, and 25% blood in RPMI 1640 –HSA) anticoagulated with hirudin. The reaction was
stopped using fluorescence-activated cell sorter lysing solution (BD Biosciences, USA). Samples were
washed with PBS supplemented with 1% bovine serum albumin (BSA; Sigma-Aldrich, Germany) and
analyzed by flow cytometry. When indicated, rSdrD at a final concentration of 3 g/ml was added to the
samples. Gating of cells was carried out on the basis of forward and side scatter. The fluorescence
intensity (FL) of 10,000 gated neutrophils was measured for each sample using a flow cytometer (BD
Biosciences, USA). Phagocytosis was identified when neutrophils expressed fluorescence. The geometric
mean of the fluorescence intensity (GMFI) was calculated using FlowJo software.
Neutrophil killing assay. Bacteria were opsonized with hirudin-anticoagulated plasma and incu-
bated with freshly isolated neutrophils at an MOI of 10 for S. aureus or an MOI of 20 for L. lactis in
siliconized tubes. rSdrD was added to a final concentration of 12 g/ml when indicated. Samples were
incubated at 37°C with vigorous shaking. After 1 h, 1 ml of ice-cold H2O supplemented with 0.3% saponin
was added, and the mixture was incubated on ice for 5 min. Surviving bacteria were quantified by serial
dilution on THB agar plates. Percent survival was determined by comparing the numbers of surviving
bacteria to the number of inoculated bacteria.
Neutrophil viability assays. Neutrophil viability in the presence of S. aureus subsp. aureus
NCTC8325-4 and NCTC8325-4 ΔsdrD was measured through LDH release (Promega, USA). Briefly,
neutrophils (2  105 cells/ml) in RPMI 1640 –HSA were seeded into a 96-well plate. Bacteria were added
to the wells at an MOI of 10 or 20. The culture supernatants were collected after 1 and 3 h, and
cytotoxicity was measured on a multimode plate reader (EnSpire Alpha; PerkinElmer, USA) according to
the manufacturer’s instructions.
NET-mediated killing assay. The NET-mediated killing assay was performed as described previously
(45) with minor modifications. Freshly isolated neutrophils (2  106 cells/ml) in RPMI 1640 –FBS were
seeded in 12-well plates and stimulated with 25 nM phorbol 12-myristate 13-acetate (PMA; Sigma-
Aldrich, Germany) for 4 h at 37°C to induce NET release. Bacteria were added at an MOI of 1, followed
by centrifugation onto the NETs (500  g, 5 min), and then incubated at 37°C for 30 min. Wells containing
bacteria without neutrophils served as a control. The content of each well was scraped thoroughly and
pipetted vigorously. Surviving bacteria were quantified by serial dilution on THB agar plates. Percent
survival was determined by comparing the numbers of surviving bacteria in the presence of NETs to the
numbers in the control wells.
Murine model of intravenous infection. An established model of S. aureus systemic infection (46)
was used to determine the difference in virulence between S. aureus subsp. aureus NCTC8325-4 and the
isogenic NCTC8325-4 ΔsdrD mutant. Eight-week-old female CD-1 mice (Charles River, Wilmington, MA,
USA) were infected intravenously with approximately 9  106 CFU of NCTC8325-4 or NCTC8325-4 ΔsdrD
bacteria by tail vein injection. The bacterial load (given as the number of CFU per gram of organ tissue
or the number of CFU per milliliter of blood) in the kidney, spleen, liver, and blood was quantified at 4
h and 4 days postinfection by homogenizing the organs and plating serial dilutions on THP agar plates.
Data represent the means  standard errors of the means (SEMs) of data from an individual experiment
for 4 h postinfection (n  8 for NCTC8325-4 and n  9 for NCTC8325-4 ΔsdrD) and the means  SEMs
of data pooled from two independent experiments for 4 days postinfection (n  8 for NCTC8325-4 and
n  9 for NCTC8325-4 ΔsdrD per experiment).
Histopathology analysis. The kidneys of the infected animals (n  6 for NCTC8325-4 and n  6 for
NCTC8325-4 ΔsdrD) were dissected and fixed in 10% paraformaldehyde (PFA) for 24 h (2 ml of PFA/100
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mg of tissue) and later moved into 70% ethanol for long-term storage until the tissues were embedded
in paraffin wax. Kidney sections (5 m thick) were deparaffinized through immersion in xylene (3 times
for 10 min each time) and rehydrated by passing them back through decreasing concentrations of
ethanol (100 and 95%, 2 times for 5 min each time). The sections were stained with hematoxylin and
eosin (H&E) and evaluated microscopically using an Olympus BX51 microscope (Olympus Europe GmbH,
Germany).
Ethical approval. Human blood analysis was carried out in accordance with the ethical principles of
the Helsinki Declaration, the medical ethics committee of the University Medical Center Utrecht (Utrecht,
The Netherlands), and ethical approval 2014/1653 REK North-Norway. Mouse studies were performed
under approved protocol S00227M of the University of California, San Diego, Institutional Animal Care
and Use Committee.
Statistical analysis. Statistical analysis of the pooled data from the experiments was carried out.
Student’s t test in Excel software (Fig. 1 to 3) and GraphPad Prism software (Fig. 4) was used for
determination of statistically significant differences between groups (P  0.05). Excel software (Fig. 1 to
3 and the figures in the supplemental material) and GraphPad Prism software (Fig. 4) were used to
generate the graphs.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
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